Key result
Echocardiographic TAPSE/sPAP ratio predicted death or clinical deterioration in PAH patients, with values <0.25 mm/mmHg indicating worse survival.
Why the study?
In pulmonary arterial hypertension, the right ventricle adapts to increased afterload by remodeling and increasing contractility to maintain ventricular-arterial coupling. This study evaluated the echocardiographic TAPSE/sPAP ratio as a surrogate of right ventricular-arterial coupling for predicting prognosis in stable PAH patients.
Does the echocardiographic TAPSE/sPAP ratio predict death or clinical deterioration and correlate with invasive hemodynamic and MRI parameters in patients with pulmonary arterial hypertension?
Cohort (n=40)
Does the echocardiographic TAPSE/sPAP ratio predict death or clinical deterioration and correlate with invasive hemodynamic and MRI parameters in patients with pulmonary arterial hypertension?
Answers are grounded in this paper and cite their sources.
Echocardiographic TAPSE/sPAP is a simple, non-invasive surrogate of right ventricular-arterial coupling that correlates strongly with invasive RHC and MRI parameters and predicts long-term clinical deterioration or death in PAH patients.
In response to an increased afterload in pulmonary arterial hypertension (PAH), the right ventricle (RV) adapts by remodeling and increasing contractility. The idea of coupling refers to maintaining a relatively constant relationship between ventricular contractility and afterload. Twenty-eight stable PAH patients (mean age 49.5 ± 15.5 years) were enrolled into the study. The follow-up time of this study was 58 months, and the combined endpoint (CEP) was defined as death or clinical deterioration. We used echo TAPSE as a surrogate of RV contractility and estimated systolic pulmonary artery pressure (sPAP) reflecting RV afterload. Ventricular–arterial coupling was evaluated by the ratio between these two parameters (TAPSE/sPAP). In the PAH group, the mean pulmonary artery pressure (mPAP) was 47.29 ± 15.3 mmHg. The mean echo-estimated TAPSE/sPAP was 0.34 ± 0.19 mm/mmHg and was comparable in value and prognostic usefulness to the parameter derived from magnetic resonance and catheterization (ROC analysis). Patients who had CEP (n = 21) had a significantly higher mPAP (53.11 ± 17.11 mmHg vs. 34.86 ± 8.49 mmHg, p = 0.03) and lower TAPSE/sPAP (0.30 ± 0.21 vs. 0.43 ± 0.23, p = 0.04). Patients with a TAPSE/sPAP lower than 0.25 mm/mmHg had worse prognosis, with log-rank test p = 0.001. the echocardiographic estimation of TAPSE/sPAP offers an easy, reliable, non-invasive prognostic parameter for the comprehensive assessment of hemodynamic adaptation in PAH patients.
No takes yet. Share an insight, caveat, or question.
Kazimierczyk et al. (2021) conducted a cohort in Pulmonary Arterial Hypertension (n=40). Echocardiographic TAPSE/sPAP ratio vs. MRI- and RHC-derived TAPSE/sPAP ratio and healthy controls was evaluated on Combined clinical endpoint (death, WHO functional class worsening, or hospitalization due to pulmonary hypertension or right heart failure requiring IV diuretics) (AUC 0.72, 95% CI 0.61-0.92, p=0.02). Echocardiographic TAPSE/sPAP ratio predicted death or clinical deterioration in PAH patients, with values <0.25 mm/mmHg indicating worse survival.
Synapse has enriched 10 related papers. Consider them for comparative context: